Myasthenia gravis treatment has seen remarkable progress, with FDA approval of a first-in-class drug targeting autoimmunity. Additionally, more than 20 therapies are currently in development, ranging from pre-clinical stages to Phase 3 trials.

This new and expanded edition explores these new therapies and other new developments in MG. The book retains its comprehensive review of MG, covering clinical presentation, laboratory and electrophysiological diagnosis, and treatment. These chapters offer neurologists and neuromuscular experts the latest insights into state-of-the-art patient care. The text then delves into focused chapters on epidemiology, genetics, and cancer-associated MG, broadening the appeal to scientists exploring the autoimmune drivers linked to tumors and the genetic underpinnings of MG pathophysiology.

Chapters on related disorders are included due to their clinical and pathological similarities to MG. These sections provide valuable insights into antibody-mediated diseases that mirror MG in their clinical manifestations. Finally, the book concludes with chapters on clinical trial design, biomarker development, and the psychological impact of MG on patients. These chapters are essential not only for academic clinical investigators but also for professionals in the pharmaceutical industry, from research scientists to clinical trial developers.

Myasthenia Gravis and Related Disorders, 4th Edition is the definitive resource for researchers and clinicians in this rapidly evolving field.

Offers a comprehensive review of MG research, diagnosis, and treatment Provides in-depth information for clinicians on the wide range of myasthenia gravis clinical presentations Thoroughly updated and expanded new edition

Autorentext

Henry J. Kaminski, MD

Meta A. Neumann Professor and Chair of Neurology

The George Washington University

Department of Neurology & Rehabilitation Medicine

2150 Pennsylvania Avenue NW

Washington, DC, 20037 USA

Linda L. Kusner, PhD

Professor

The George Washington University

Department of Pharmacology and Physiology

2300 Eye St NW

Washington, DC, 20037 USA

Inhalt

Chapter 1. Neuromuscular Junction Physiology and Pathophysiology.- Chapter 2. Acetylcholine Receptor Structure.- Chapter 3. Immunopathogenesis of Myasthenia Gravis.- Chapter 4. Animal Models of Myasthenia Gravis for Preclinical Evaluation.- Chapter 5. Epidemiology and Genetics of Myasthenia Gravis.- Chapter 6. Clinical Presentations of Myasthenia Gravis.- Chapter 7. Ocular Myasthenia.- Chapter 8. Thymoma-associated Myasthenia Gravis.- Chapter 9. Electrodiagnosis of Neuromuscular Junction Disorders.- Chapter 10. Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases.- Chapter 11. Treatment of Myasthenia Gravis.- Chapter 12. Neurocritical Care of Myasthenic Crisis.- Chapter 13. Thymectomy for Non-thymomatous Myasthenia Gravis.- Chapter 14. Lambert-Eaton Syndrome.- Chapter 15 Acquired Neuromyotonia.- Chapter 16. Congenital Myasthenic Syndromes.- Chapter 17. Toxic Neuromuscular Transmission Disorders.- Chapter18. Predictors of Psychological Health in Myasthenia Gravis.- Chapter 19. Myasthenia Gravis: Classification and Outcome Measurements.- Chapter 20. Emerging Therapeutics for Myasthenia Gravis.- Chapter 21. Clinical Trial Design for Myasthenia Gravis.